14 oktober 2011: Bron: Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Aug;31(8):1062-5.

Longkankerpatienten met tumoren in het longvocht kunnen de behandeling met lentinan verbeteren door er lokale hyperthermie bij te doen. Lentinan is een niet toxisch Chinees voedingsupplement gemaakt van bepaalde paddestoelen en wordt in China vaak gegeven d.m.v. een injectie i.p.v. chemo. Nu blijkt dat de effectiviteit van de behandeling nog verbeterde als na de injectie een uur lokale hyperthermie werd gegeven op de borst. De effectiviteit steeg met 10% van 73,3 naar 83,3%. Er werden verder geen ernstige bijwerkingen geconstatateerd maar ook bij lentinan zijn die bijwerkingen minimaal. Dit alles bljkt uit een gerandomiseerde fase II studie bij totaal 60 longkankerpatienten met tumoren in het longvocht. Hier het abstract van de studie:

Thermotherapy combined with thoracic injection of lentinan showed better effect in treatment of cancerous hydrothorax in patients with lung cancer. No obvious adverse reaction was seen

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Aug;31(8):1062-5.

[Clinical observation of thermotherapy combined with thoracic injection of lentinan in treatment of cancerous hydrothorax of patients with lung cancer].

[Article in Chinese]

Li XJ, Jia YJ, Chen L.

Source

Department of Oncology, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193.

Abstract

OBJECTIVE:

To study the therapeutic effect and mechanism of thermotherapy combined with thoracic injection of lentinan in treatment of cancerous hydrothorax (CH) in patients with lung cancer.

METHODS:

Sixty lung cancer patients complicated with CH were randomly assigned to the observation group and the control group, 30 in each. CH was released by closed drainage of the thoracic cavity in all patients. Thermotherapy was given to patients in the observation group after lentinan was thoracically injected, while lentinan was thoracically injected to patients in the control group.

RESULTS:

The total effective rate of CH improvement was 73.3% (22/30) in the control group and 83.3% (25/30) in the observation group, showing insignificant difference (P>0.05). The stability rate and the weight stability rate by Karnofsky's performance scoring in the observation group were superior to those of the control group, showing significant difference (P<0.05). No hematological reaction, hepatic or renal damage occurred before and after treatment in both groups. Fever, thoracalgia, dyspnea, rash, nausea and vomit appeared in few patients of the two groups, showing insignificant difference (P>0.05). CD3+, CD4+, CD4+/CD8+, and NK obviously increased and CD8+ decreased in the observation group after treatment, showing significant difference from those before treatment (P<0.05). Compared with the control group after treatment, CD3+, CD4+, CD4+/CD8+, and NK obviously increased, CD8+ increased in the observation group (P<0.05).

CONCLUSION:

Thermotherapy combined with thoracic injection of lentinan showed better effect in treatment of CH in patients with lung cancer. No obvious adverse reaction was seen.